Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0KV2E
|
||||
Former ID |
DNCL002397
|
||||
Drug Name |
Sonepcizumab
|
||||
Drug Type |
Antibody
|
||||
Indication | Macular degeneration [ICD9: 362.5; ICD10:H35.3] | Phase 1 | [522296] | ||
Company |
Lpath
|
||||
Target and Pathway | |||||
Target(s) | Sphingosine 1-phosphate receptor 1 | Target Info | [531633], [532456], [550421] | ||
References | |||||
Ref 531633 | Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model. J Glaucoma. 2013 Feb;22(2):145-51. | ||||
Ref 532456 | Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. | ||||
Ref 550421 | National Cancer Institute Drug Dictionary (drug id 595163). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.